Mosunetuzumab (Lunsumio)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.

Diseases for which it is used

History of changes in FDA indication

  • 2022-12-22: Initial approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. (Based on GO29781)

History of changes in EMA indication

  • 2022-06-03: Initial conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

Also known as

  • Code names: BTCT4465A, RG7828
  • Generic name: mosunetuzumab-axgb
  • Brand name: Lunsumio